Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 November 2022 | Story André Damons

The Department of Pharmacology at the University of the Free State (UFS), together with the Technology Innovation Agency (TIA), is hosting the first Indigenous Knowledge and Bio-Trade Indaba on the Bloemfontein Campus. The Department of Science and Innovation (DSI) and TIA are the sponsors of the event. 

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, will play host to the various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, innovation, and commercialisation of the IK-based research products. The Indigenous Knowledge System (IKS) for Health unit in the Department of Pharmacology within the UFS Faculty of Health Sciences was last year awarded an annual Technology Innovation Agency Platform (TIA) grant of R17 million for the next five years.

The research and teaching programme in the School of Clinical Medicine has since been rebranded and is now known as the African Medicines Innovation and Technology Development Platform (AMITD), which will strive to respond to community health needs and address industry research needs and challenges.

The indaba will showcase progress made by TIA and other entities in enriching the development and commercialisation of IK-based innovations. It will take place from 24 to 25 November 2022 in the Equitas Senate Hall at the UFS. 

Prof Matsabisa is the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19. He is also a visiting professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, and the Deputy President of the South African Society for Basic and Clinical Pharmacology.
 

News Archive

Counterfeit HIV / AIDS drugs must be dealt with
2006-02-16

Some of the guests attending the lecture were from the left Prof Johan Henning (Dean:  UFS Faculty of Law), Dr Jayasuriya, Prof Voet du Plessis (Head: UFS Department of Mercantile Law) and Dr Ezekiel Moraka (Vice-Rector:  Student Affairs at the UFS).
Photo: Stephen Collett

Counterfeit HIV / AIDS drugs must be dealt with

An international legal expert who has worked with various UN agencies has called on governments to deal quickly and decisively with people dealing in counterfeit HIV / AIDS drugs.

The Vice-President of the Global Jurists Foundation and former head of the UNAIDS secretariat in Pakistan, Dr Dayanath Jayasuriya, was speaking at the University of the Free State in Bloemfontein.

Delivering a guest lecture on HIV/ AIDS and human rights in developing countries, Dr Jayasuriya said counterfeit drugs were spreading at an alarming rate throughout the world.  He said that in particular counterfeit HIV / AIDS drugs contribute to the vulnerability of persons living with HIV / AIDS.

“Only a few countries have integrated anti-counterfeit drug provisions into national legislation on medicinal drugs” he said.
According to Dr Jayasuriya, the violation of the rights of people living with HIV / AIDS is continuing despite the fact that many governments have adopted various charters and declarations that are meant to guarantee the human rights of citizens.

He said these violations have included the brutal murder of persons with HIV / AIDS.

Other violations include verbal abuse and physical injuries through acts of torture; deprivation or denial of access to employment; medical facilities, including drugs; accommodation; food; social service benefits; insurance; custody of children, and so on.

“In recorded human history HIV / AIDS is by no means the first ever major public health epidemic to confront human kind. However, none of the other epidemics generated the same degree and intensity of human rights concerns,” Dr Jayasuriya said.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept